News
![Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for Rubraca® (rucaparib)
![Morphosys: Wer hätte das gedacht?](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Morphosys: Wer hätte das gedacht?
Morphosys-Aktien (WKN: 663200) verloren gestern im Handelsverlauf fast 23 Euro im Xetra-Handel. Ein so eklatanter Rutsch kam wohl auch für pessimistische Anleger überraschend.
Egal, was der
![Evotec: Es geht Schlag auf Schlag](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Evotec: Es geht Schlag auf Schlag
Ausnahmsweise ist die von Evotec (WKN: 566480) im Rahmen seiner heutigen Pressemitteilungen kommunizierte hochkarätige Forschungspartnerschaft nur eine (positive) Randnotiz. Diesmal geht es primär
![ICON Issues Financial Guidance for Full Year 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
ICON Issues Financial Guidance for Full Year 2020
ICON plc (NASDAQ: ICLR), global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health
![Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Ipsen Appoints Steven Hildemann, MD., PhD as Executive Vice President, Chief Medical Officer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200113005846/en/
(Photo: Business Wire)
Ipsen (Euronext: IPN; ADR
![QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
QIAGEN Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration to develop tissue-based companion diagnostics for Amgen’s investigational cancer treatment AMG 510
![QIAGEN erweitert globale Zusammenarbeit mit Amgen zur Entwicklung von Begleitdiagnostika bei nicht-kleinzelligem Lungenkrebs](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
QIAGEN erweitert globale Zusammenarbeit mit Amgen zur Entwicklung von Begleitdiagnostika bei nicht-kleinzelligem Lungenkrebs
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute eine strategische Zusammenarbeit zur Entwicklung von gewebebasierten Begleitdiagnostika für Amgens Krebsmedikament AMG 510 bekannt
![Biofrontera: Es ist wieder Musik in der Aktie](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Biofrontera: Es ist wieder Musik in der Aktie
Die Biofrontera-Aktie (WKN: 604611) bewegt sich am Montag explosionsartig über die 5-Euro-Marke. Besser als erwartete Umsatzzahlen für 2019 locken Anleger in den deutschen Pharma-Qualitätstitel.
![ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
ICON plc to Present at 38th Annual J.P. Morgan Healthcare Conference and Issue Financial Guidance for Full Year 2020
ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health
![Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Charles River and Takeda Announce Scientific Collaboration to Identify and Develop Preclinical Candidates
Charles River (NYSE: CRL) today announced a multi-year drug discovery collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). Together, Charles River and Takeda will launch multiple
![Charles River Laboratories to Present at J.P. Morgan Healthcare Conference](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Charles River Laboratories to Present at J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday
![Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that its Chief Executive Officer and President, Alan H. Auerbach, will be presenting at the 38th Annual J.P. Morgan
![Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Antibe Therapeutics Expands Executive Team in Preparation for Large Market Partnering
Antibe Therapeutics Inc. ("Antibe" or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce the hiring
![Novus Therapeutics Provides Update on OP0201](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Novus Therapeutics Provides Update on OP0201
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today provided an update on the
![Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update
Novocure (NASDAQ: NVCR) today reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2019. Novocure plans to discuss these
![Morphosys: Milliarden für Anti-Krebs-Blockbuster](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Morphosys: Milliarden für Anti-Krebs-Blockbuster
Morphosys-Aktien (WKN: 663200) steigen im Xetra-Handel auf bis zu 146,30 Euro. Grund ist ein milliardenschwerer Deal für den firmeneigenen Anti-Krebs-Wirkstoff Tafasitamab mit dem Biopharma-Bluechip
![Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Novus Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced the
![Medigene: Gewaltige Kursgewinne nach super Daten!](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Medigene: Gewaltige Kursgewinne nach super Daten!
Positive Studienergebnisse beflügeln die Aktien von Medigene (WKN: A1X3W0). Auf Xetra geht der Biotech-Wert mit einem Tagesplus von +33,35% auf 5,55 Euro aus dem Handel. Auf Tradegate steigt der
![QIAGEN N.V. to Report Fourth Quarter and Full Year 2019 Results](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
QIAGEN N.V. to Report Fourth Quarter and Full Year 2019 Results
QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans as previously announced to release its report on results for the fourth quarter and full-year 2019 on Tuesday
![Applied Genetic Technologies: Kursfeuerwerk nach guten Studiendaten!](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Applied Genetic Technologies: Kursfeuerwerk nach guten Studiendaten!
Zu einem regelrechten Kursfeuerwerk kam es gestern bei der Aktie von Applied Genetic Technologies (WKN: A110V2), der Kurs konnte sich gestern von 4,16 auf 9,27 USD mehr als verdoppeln.
Grund für
![Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
Sensorion Announces its Presence in San Francisco during the 38th annual J.P. Morgan Healthcare Conference
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 8, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
![QIAGEN Celebrates Surpassing 2,500 Cumulative Placements of QIAsymphony](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
QIAGEN Celebrates Surpassing 2,500 Cumulative Placements of QIAsymphony
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the 2,500th placement of QIAsymphony, the leading Sample to Insight workflow automation solution for molecular laboratories
![QIAGEN feiert mehr als 2.500 QIAsymphony-Platzierungen](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
QIAGEN feiert mehr als 2.500 QIAsymphony-Platzierungen
QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) gab heute in Tübingen die 2.500. Platzierung eines QIAsymphony Geräts bekannt, der führenden Automatisierungslösung für „Sample to
![Morphosys: Beste Perspektiven](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Morphosys: Beste Perspektiven
Der Morphosys-Konzern (WKN: 663200) meldete sich zuletzt mit wichtigen medizinischen Updates, die es aufgrund ihrer Signifikanz zu beleuchten gilt.
Der Initiation der Phase 1-Studie von Tafasitamab